RVNC - Revance Therapeutics GAAP EPS of -$0.58 revenue of $51.94M
2024-05-09 16:50:00 ET
More on Revance Therapeutics
- Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript
- Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
- Revance Therapeutics Q1 2024 Earnings Preview
- Survey finds GLP-1 users more inclined to get aesthetic procedures
- Seeking Alpha’s Quant Rating on Revance Therapeutics